Gay, F
Oliva, S
Petrucci, M T
Montefusco, V
Conticello, C
Musto, P
Catalano, L
Evangelista, A
Spada, S
Campbell, P
Ria, R
Salvini, M
Offidani, M
Carella, A M
Omedé, P
Liberati, A M
Troia, R
Cafro, A M
Malfitano, A
Falcone, A P
Caravita, T
Patriarca, F
Nagler, A
Spencer, A
Hajek, R
Palumbo, A
Boccadoro, M
Article History
Received: 16 September 2016
Revised: 28 October 2016
Accepted: 7 November 2016
First Online: 23 December 2016
Competing interests
: FG has received honoraria from Amgen, BMS, Celgene and Takeda, and served on the advisory committee for Janssen, Mundipharma, and Takeda. SO has received honoraria from Takeda and Celgene. MTP has received honoraria from Celgene, Janssen-Cilag, Bristol-Myers Squibb, Amgen, Takeda, Mundipharma, Sanofi. PM has received honoraria from Celgene, Janssen, Novartis, Sanofi, Bristol-Myers Squibb, Takeda, Amgen. MO has received honoraria from Celgene. TC has received honoraria from Celgene, Janssen, Amgen, Bristol-Myers Squibb, and consultancy fees from Takeda. FP has received honoraria from MSD Italia, Celgene, and served on the advisory board of Janssen, Mundipharma, Amgen, Bristol-Meyers Squibb. AS has received honoraria from Celgene. RH has received consultancy fees from Celgene, Janssen, and honoraria from Amgen. AP has received consultancy fees, honoraria and research funding from Celgene, and is a Takeda employee. MB has received consultancy fees from Janssen, Sanofi, Onyx, Amgen, Celgene. The remaining authors declare no conflict of interest.